Clinical effects of 3% diquafosol ophthalmic solution in dry eye disease patients using VDT

Clinical effects of 3% diquafosol ophthalmic solution in dry eye disease patients using VDT - Clinical effects of 3% diquafosol ophthalmic solution in dry eye disease patients using VDT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008990

Enrollment

100

Registered

2012-09-27

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Interventions

3% diquafosol ophthalmic solutions

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Definite and probable dry eye disease patients diagnosed according to the criteria of dry eye disease 2)Patients who gave consent to participation in this trial 3)Patients who will be able to consult a physician throughout the observation period

Exclusion criteria

Exclusion criteria: 1) Patients who had allergic conjunctivitis, uveitis or diabetic keratopathy 2)Patients who are satisfied with the current treatment for dry eye 3)Patients determined as ineligible for the study by the attending physician

Design outcomes

Secondary

Measure	Time frame
Changes in fluorescein staining scores and BUT	—

Primary

Measure	Time frame
Changes in subjective symptoms	—

Countries

Japan

Contacts

Public ContactYuichi Uchino

Tokyo Electric Power hospital Ophthalmology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026